Skip to content
Evigrade
CriticalAntidepressant, norepinephrine-dopamine reuptake inhibitor (NDRI); a separate formulation (Zyntabac) is licensed for smoking cessation×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B)

Updated · Methodology

Mechanism

Bupropion selectively inhibits the neuronal reuptake of noradrenaline and dopamine and does not inhibit monoamine oxidase (MAO) itself (bupropion summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). MAO type A and B inhibitors also enhance catecholamine signalling, by a different mechanism, and together with bupropion they make adverse reactions more likely (bupropion SmPC, AEMPS, section 4.5). Phenelzine is an MAO inhibitor (phenelzine label, US Food and Drug Administration, FDA, Precautions), and combining MAO inhibitors with bupropion increases the risk of hypertensive reactions (FDA bupropion label, sections 4 and 7.6). In animal studies, phenelzine enhanced the acute toxicity of bupropion (FDA bupropion label, section 7.6).

Symptoms

The main risk of the combination is hypertensive reactions (bupropion label, US Food and Drug Administration, FDA, sections 4 and 7.6). A hypertensive crisis with phenelzine presents with an occipital headache that may spread to the forehead, palpitations, neck stiffness or soreness, nausea, vomiting, sweating (sometimes with fever and sometimes with cold, clammy skin), dilated pupils and sensitivity to light. The heart rate may be fast or slow, sometimes with constricting chest pain. Intracranial bleeding has occurred with the rise in blood pressure, and some crises have been fatal (FDA phenelzine label, Warnings). Bupropion itself can raise blood pressure, sometimes severely enough to need urgent treatment (bupropion summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4).

Management

The combination is contraindicated. The Spanish bupropion summary of product characteristics (SmPC) prohibits bupropion with monoamine oxidase (MAO) inhibitors (bupropion SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The US phenelzine label explicitly contraindicates combining an MAO inhibitor with bupropion (phenelzine label, US Food and Drug Administration, FDA, Contraindications). The US bupropion label also contraindicates MAO inhibitors used for psychiatric disorders (FDA bupropion label, section 4), and phenelzine is used for depression (FDA phenelzine label, Indications). Phenelzine is not authorised in Spain (AEMPS medicines register), so information on it comes from the US label. Start bupropion no earlier than 14 days after stopping phenelzine (FDA phenelzine label, Contraindications; FDA bupropion label, sections 2.8 and 4). The Spanish bupropion SmPC requires at least 14 days after irreversible MAO inhibitors and considers 24 hours enough after reversible ones (bupropion SmPC, AEMPS, section 4.3). Start phenelzine no earlier than 14 days after stopping bupropion (FDA bupropion label, sections 2.8 and 4). Measure blood pressure before starting bupropion and monitor it during treatment (bupropion SmPC, AEMPS, section 4.4). With phenelzine, check blood pressure often and stop phenelzine at once if palpitations or frequent headaches appear (FDA phenelzine label, Warnings). In a hypertensive crisis, stop phenelzine and start lowering blood pressure immediately. The US phenelzine label recommends phentolamine (a reported dose of 5 mg intravenously), given slowly to avoid an excessive fall in blood pressure, and fever is managed with external cooling (FDA phenelzine label, Warnings).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Bupropion

Other interactions with Phenelzine